HomeCompareEPDPX vs ABBV

EPDPX vs ABBV: Dividend Comparison 2026

EPDPX yields 5.68% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPDPX wins by $12847.72M in total portfolio value
10 years
EPDPX
EPDPX
● Live price
5.68%
Share price
$14.91
Annual div
$0.85
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$12847.82M
Annual income
$12,427,818,421.10
Full EPDPX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — EPDPX vs ABBV

📍 EPDPX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEPDPXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EPDPX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EPDPX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EPDPX
Annual income on $10K today (after 15% tax)
$483.17/yr
After 10yr DRIP, annual income (after tax)
$10,563,645,657.94/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, EPDPX beats the other by $10,563,624,601.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EPDPX + ABBV for your $10,000?

EPDPX: 50%ABBV: 50%
100% ABBV50/50100% EPDPX
Portfolio after 10yr
$6423.96M
Annual income
$6,213,921,596.43/yr
Blended yield
96.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

EPDPX
No analyst data
Altman Z
3.0
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EPDPX buys
0
ABBV buys
0
No recent congressional trades found for EPDPX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEPDPXABBV
Forward yield5.68%3.06%
Annual dividend / share$0.85$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$12847.82M$102.3K
Annual income after 10y$12,427,818,421.10$24,771.77
Total dividends collected$12818.62M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EPDPX vs ABBV ($10,000, DRIP)

YearEPDPX PortfolioEPDPX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,837$1,136.86$11,550$430.00+$287.00EPDPX
2$15,181$2,515.30$13,472$627.96+$1.7KEPDPX
3$22,273$6,029.66$15,906$926.08+$6.4KEPDPX
4$40,368$16,535.83$19,071$1,382.55+$21.3KEPDPX
5$99,212$56,018.25$23,302$2,095.81+$75.9KEPDPX
6$363,494$257,337.31$29,150$3,237.93+$334.3KEPDPX
7$2,151,248$1,762,309.45$37,536$5,121.41+$2.11MEPDPX
8$21,796,756$19,494,920.82$50,079$8,338.38+$21.75MEPDPX
9$392,528,781$369,206,251.51$69,753$14,065.80+$392.46MEPDPX
10$12,847,824,217$12,427,818,421.10$102,337$24,771.77+$12847.72MEPDPX

EPDPX vs ABBV: Complete Analysis 2026

EPDPXStock

Under normal market conditions, the fund will invest at least 80% of its net assets (plus any borrowings for investment purposes) in equity securities of dividend paying companies located in Europe or the Pacific Rim. It will invest primarily in non-U.S. companies. The fund may invest in companies of all capitalizations that the advisor considers to be attractive dividend paying companies.

Full EPDPX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this EPDPX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EPDPX vs SCHDEPDPX vs JEPIEPDPX vs OEPDPX vs KOEPDPX vs MAINEPDPX vs JNJEPDPX vs MRKEPDPX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.